Sun Pharma to Acquire Organon in $11.75 Billion Deal

Sun Pharmaceutical Industries Limited has announced a landmark agreement to acquire Organon & Co. in an all-cash transaction valued at approximately $11.75 billion. Under the terms of the deal, Sun Pharma will purchase all outstanding shares of Organon at $14.00 per share, marking one of the largest acquisitions in the global pharmaceutical sector in recent years.

Organon, which was spun off from Merck & Co. in 2021, has established itself as a major player in women’s health and general medicines. The company operates across more than 140 countries and offers a portfolio of over 70 products, including biosimilars and established therapies. Its strong presence in key markets such as the United States, Europe, China, Canada, and Brazil is supported by six manufacturing facilities across the European Union and emerging markets.

The acquisition aligns with Sun Pharma’s long-term strategy to expand its innovative medicines portfolio while strengthening its position in branded generics and established products. Following completion of the transaction, the combined entity is expected to rank among the top 25 global pharmaceutical companies, with projected combined revenues of approximately $12.4 billion.

The deal is also set to significantly enhance Sun Pharma’s global footprint and capabilities. The combined company will operate in around 150 countries and is expected to become a top-three player in women’s health globally. Additionally, the acquisition provides Sun Pharma with a strong entry into the biosimilars segment, where it is projected to become the seventh-largest player worldwide.

From a financial perspective, the transaction is anticipated to nearly double Sun Pharma’s EBITDA and cash flow, strengthening its ability to generate long-term value. While the deal will initially increase leverage, the company expects to deleverage over time through improved cash generation and operational synergies.

Leadership from both organizations emphasized the strategic importance of the agreement. Sun Pharma’s Executive Chairman, Dilip Shanghvi, described the acquisition as a major step toward building a more diversified and globally competitive platform. He noted that Organon’s capabilities and portfolio complement Sun Pharma’s existing strengths.

Organon’s Executive Chair, Carrie Cox, highlighted that the transaction delivers immediate and compelling value to shareholders following a comprehensive review of strategic alternatives. She also expressed confidence in Sun Pharma’s ability to support Organon’s global operations, workforce, and mission to deliver impactful healthcare solutions.

The transaction has been approved by the boards of both companies and is subject to customary closing conditions, including regulatory approvals and approval by Organon’s shareholders. Once completed, the deal is expected to reshape Sun Pharma’s position in the global pharmaceutical landscape, reinforcing its ambition to expand access to medicines and drive sustainable growth.